In the past few months, we have talked a lot about high-cost drugs. We've done episodes on new innovations, equity implications, the rise of weight management drugs and more. While there is a lot to be excited about, there is a lot to be anxious about too, like high costs and impending legislation. A lot of the industry is tempted to "wait and see" what the new era of drugs will bring, but the reality is that "new era" is already here.
That's why, in this episode, host Rachel (Rae) Woods invites Advisory Board pharmacy experts Rachael Peroutky and Chloe Bakst to discuss how the industry should be thinking about this new era of drugs, and why healthcare organizations can't afford to sit around today and strategize later.
Links:

Ep. 177: Advancing equity in a world of innovation for some, costs for all: Live from the 2023 Clinical Innovation Summit
Ep. 167: How nervous should we be about high-cost drugs?
Ep. 159: Ozempic, Wegovy, and our questions on weight management drugs
[Webinar Recording] State of the Industry: How high-cost drugs change everything


Read Advisory Board's case study about how University of Michigan Health-West improved clinician well-being with Nuance's Dragon Ambient eXperience (DAX).

A transcript of this episode as well as more information and resources can be found on radioadvisory.advisory.com.